Why the study?
What is the optimal dosing of anticoagulants for safety and efficacy in obese patients requiring VTE treatment or prophylaxis?
What is the optimal dosing of anticoagulants for safety and efficacy in obese patients requiring VTE treatment or prophylaxis?
In obese patients, weight-based dosing is preferred for UFH and LMWH, fondaparinux requires dose adjustment, while DOACs can be given at fixed doses for VTE management.
No takes yet. Share an insight, caveat, or question.
May inform anticoagulant dosing in obese VTE patients; leaves open need for prospective RCTs to confirm strategies.
Ihaddadene et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: